162 related articles for article (PubMed ID: 11318793)
1. Oncogenic osteomalacia associated with mesenchymal tumour detected by indium-111 octreotide scintigraphy.
Rhee Y; Lee JD; Shin KH; Lee HC; Huh KB; Lim SK
Clin Endocrinol (Oxf); 2001 Apr; 54(4):551-4. PubMed ID: 11318793
[TBL] [Abstract][Full Text] [Related]
2. Octreotide scanning in the detection of a mesenchymal tumour in the pubic symphysis causing hypophosphataemic osteomalacia.
Moran M; Paul A
Int Orthop; 2002; 26(1):61-2. PubMed ID: 11954853
[TBL] [Abstract][Full Text] [Related]
3. [Detection of the primary tumor site in tumor-induced osteomalacia by indium-111 octreotide scintigraphy: a case report].
Takahashi M; Toru S; Ota K; Izumiyama H; Yokota T; Mizusawa H
Rinsho Shinkeigaku; 2008 Feb; 48(2):120-4. PubMed ID: 18326305
[TBL] [Abstract][Full Text] [Related]
4. Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia.
Nguyen BD; Wang EA
Clin Nucl Med; 1999 Feb; 24(2):130-1. PubMed ID: 9988077
[No Abstract] [Full Text] [Related]
5. Oncogenic osteomalacia: two case reports with surprisingly different outcomes.
Seijas R; Ares O; Sierra J; Pérez-Dominguez M
Arch Orthop Trauma Surg; 2009 Apr; 129(4):533-9. PubMed ID: 19125258
[TBL] [Abstract][Full Text] [Related]
6. Bone and In-111 octreotide imaging in oncogenic osteomalacia: a case report.
Garcia CA; Spencer RP
Clin Nucl Med; 2002 Aug; 27(8):582-3. PubMed ID: 12170004
[TBL] [Abstract][Full Text] [Related]
7. Localisation of mesenchymal tumours by somatostatin receptor imaging.
Jan de Beur SM; Streeten EA; Civelek AC; McCarthy EF; Uribe L; Marx SJ; Onobrakpeya O; Raisz LG; Watts NB; Sharon M; Levine MA
Lancet; 2002 Mar; 359(9308):761-3. PubMed ID: 11888589
[TBL] [Abstract][Full Text] [Related]
8. En bloc resection for treatment of tumor-induced osteomalacia: a case presentation and a systematic review.
Meng T; Zhou W; Li B; Yin H; Li Z; Zhou L; Kong J; Yan W; Yang X; Liu T; Song D; Xiao J
World J Surg Oncol; 2015 May; 13():176. PubMed ID: 25951872
[TBL] [Abstract][Full Text] [Related]
9. [Oncogenic osteomalacia in a 49-year-old female patient].
Ludwig J; Mechtersheimer G; Haberkorn U; Nawroth P; Schilling T; Kasperk C
Dtsch Med Wochenschr; 2005 Feb; 130(5):206-9. PubMed ID: 15678388
[TBL] [Abstract][Full Text] [Related]
10. Indium-111 octreotide scintigraphy in patients with bone tumours of the extremities.
Inanir S; Unlü M; Okudan B; Cila E; Atik S
Eur J Nucl Med; 1996 Aug; 23(8):987-90. PubMed ID: 8753691
[TBL] [Abstract][Full Text] [Related]
11. The levels of somatostatin receptors in causative tumors of oncogenic osteomalacia are insufficient for their agonist to normalize serum phosphate levels.
Ishii A; Imanishi Y; Kobayashi K; Hashimoto J; Ueda T; Miyauchi A; Koyano HM; Kaji H; Saito T; Oba K; Komatsu Y; Kurajoh M; Nagata Y; Goto H; Wakasa K; Sugimoto T; Miki T; Inaba M; Nishizawa Y
Calcif Tissue Int; 2010 Jun; 86(6):455-62. PubMed ID: 20458578
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia.
Duet M; Kerkeni S; Sfar R; Bazille C; Lioté F; Orcel P
Clin Nucl Med; 2008 Nov; 33(11):752-6. PubMed ID: 18936605
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor expression in an epitheloid hemangioma causing oncogenic osteomalacia.
Müssig K; Oksüz MO; Pfannenberg C; Adam P; Zustin J; Beckert S; Petersenn S
J Clin Endocrinol Metab; 2009 Nov; 94(11):4123-4. PubMed ID: 19789203
[No Abstract] [Full Text] [Related]
14. Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide.
Krenning EP; Kwekkeboom DJ; de Jong M; Visser TJ; Reubi JC; Bakker WH; Kooij PP; Lamberts SW
Semin Oncol; 1994 Oct; 21(5 Suppl 13):6-14. PubMed ID: 7992084
[No Abstract] [Full Text] [Related]
15. Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography.
Hesse E; Moessinger E; Rosenthal H; Laenger F; Brabant G; Petrich T; Gratz KF; Bastian L
J Bone Miner Res; 2007 Jan; 22(1):158-62. PubMed ID: 17014386
[TBL] [Abstract][Full Text] [Related]
16. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin and the concept of peptide receptor scintigraphy in oncology.
Lamberts SW; Reubi JC; Krenning EP
Semin Oncol; 1994 Oct; 21(5 Suppl 13):1-5. PubMed ID: 7992074
[No Abstract] [Full Text] [Related]
18. Evaluation of tumor-induced osteomalacia with 111In-pentetreotide scintigraphy.
Palot Manzil FF; Bhambhvani PG; O'Malley JP
J Nucl Med Technol; 2013 Dec; 41(4):299-301. PubMed ID: 24159011
[TBL] [Abstract][Full Text] [Related]
19. Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients.
Zuo QY; Wang H; Li W; Niu XH; Huang YH; Chen J; You YH; Liu BY; Cui AM; Deng W
BMC Musculoskelet Disord; 2017 Sep; 18(1):403. PubMed ID: 28934935
[TBL] [Abstract][Full Text] [Related]
20. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M
Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
